Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Glucotrack, Inc.GCTK · Entity 8422 | Director | March 25, 2025 | October 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Glucotrack, Inc.
Report date March 25, 2025 · Filed October 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 4,692 |
Ending reported balance
After 2025-10-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-25 · Grant · Acquired 75 · Balance 75 Row 2 · 2025-07-11 · Grant · Acquired 3,332 · Balance 3,407 Row 3 · 2025-10-03 · Grant · Acquired 1,285 · Balance 4,692 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.40 · Expires 2035-10-03 | Direct | 4,055 |
Reported balance
After 2025-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-03 · Grant · Acquired 4,055 · Balance 4,055 F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DEXCOM INC
Report date March 10, 2023 · Filed March 14, 2023
Section 16 reporting ended · disclosed 2023-03-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,908 |
Last balance in matching sequence
After 2023-03-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,275 · Balance 59,303 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 2 · 2023-03-10 · Disposition to issuer · Disposed 2,405 · Balance 56,898 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 3 · 2023-03-10 · Disposition to issuer · Disposed 5,990 · Balance 50,908 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 30,212 |
Reported balance
Holding disclosure · report date 2023-03-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,212 F3: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
F3: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2025 Filed Oct 7, 2025 21:38 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantStock option (right to buy) · Derivative | 4,055 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001323190-25-000003 · primary_doc.xml · derivative · entry 4 Balo Andrew K · CIK 0001323190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,055 Underlying: Common Stock, par value $0.001 per share · 4,055 shares Expires 2035-10-03 F1 · derivative.exercise_date: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:38 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 1,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001323190-25-000003 · primary_doc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,692 Read SEC document |
| July 11, 2025 Filed Oct 7, 2025 21:38 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 3,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001323190-25-000003 · primary_doc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,407 Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:57 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 4,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000067 · primary_doc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,490 Read SEC document |
| March 25, 2025 Filed Oct 7, 2025 21:38 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 75 | $0.00 | $0.00 |
DisclosureSEC source: 0001323190-25-000003 · primary_doc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:45 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 5,990 | $111.40 | $667,280.01 |
DisclosureSEC source: 0001093557-23-000075 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP Regulatory Strategy Clinic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,908 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:45 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,405 | $111.40 | $267,914.60 |
DisclosureSEC source: 0001093557-23-000075 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP Regulatory Strategy Clinic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,898 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:45 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,275 | $111.40 | $364,831.73 |
DisclosureSEC source: 0001093557-23-000075 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP Regulatory Strategy Clinic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,303 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:22 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 949 | $406.06 | $385,347.81 |
DisclosureSEC source: 0001093557-22-000045 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · EVP, Global Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,615 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:22 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,549 | $406.06 | $628,981.83 |
DisclosureSEC source: 0001093557-22-000045 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Global Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,564 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:22 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 932 | $406.06 | $378,444.84 |
DisclosureSEC source: 0001093557-22-000045 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Global Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,113 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:22 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 4,984 | $0.00 | $4.98 |
DisclosureSEC source: 0001093557-22-000045 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Global Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,045 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $551.45 | $27,572.50 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 12 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,553 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,200 | $550.36 | $660,433.44 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 11 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,603 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $549.99 to $550.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,261 | $549.43 | $692,836.90 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 10 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,803 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $548.93 to $549.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 750 | $548.24 | $411,178.58 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 9 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,064 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $547.80 to $548.65. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 550 | $547.35 | $301,040.41 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 8 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,814 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $546.745 to $547.740. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $543.66 | $27,183.00 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 7 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,364 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $542.83 | $108,566.00 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 6 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,414 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 273 | $541.33 | $147,782.27 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 5 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,614 F5 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $541.27 to $541.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 15 | $541.76 | $8,126.40 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,887 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,248 | $541.36 | $675,617.28 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,902 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 2,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,150 F1 · shares: Shares were transferred from direct ownership to ownership under the Balo Family Trust upon vesting of previously awarded restricted stock units. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 2,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000223 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,056 F1 · shares: Shares were transferred from direct ownership to ownership under the Balo Family Trust upon vesting of previously awarded restricted stock units. F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 349 | $519.92 | $181,451.87 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 8 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,652 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $519.64 to $520.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 525 | $519.24 | $272,598.48 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 7 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,001 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $518.60 to $519.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $518.06 | $103,611.32 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 6 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,526 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $517.600 to $518.515. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $516.72 | $103,344.50 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 5 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,726 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $516.425 to $517.020. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $515.33 | $154,598.01 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,926 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $515.00 to $515.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $514.18 | $154,253.13 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,226 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $513.59 to $514.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $512.83 | $102,565.50 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,526 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $512.46 to $513.39. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 00:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 683 | $512.19 | $349,823.86 |
DisclosureSEC source: 0001093557-21-000195 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,726 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $511.45 to $512.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 286 | $432.05 | $123,565.70 |
DisclosureSEC source: 0001093557-21-000177 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,409 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $431.455 to $432.050. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,710 | $430.56 | $736,253.50 |
DisclosureSEC source: 0001093557-21-000177 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,695 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $430.270 to $430.919. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $429.33 | $171,732.40 |
DisclosureSEC source: 0001093557-21-000177 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,405 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $429.141 to $429.401. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 578 | $428.51 | $247,676.24 |
DisclosureSEC source: 0001093557-21-000177 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,805 F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $428.125 to $429.060. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,391 | $375.00 | $896,625.00 |
DisclosureSEC source: 0001093557-21-000164 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,383 F4 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:33 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 18,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000164 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 18,774 F1 · shares: Shares were transferred from direct ownership to ownership under the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. F3 · balance_after: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:33 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 18,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000164 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,533 F1 · shares: Shares were transferred from direct ownership to ownership under the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,566 | $362.92 | $2,019,996.02 |
DisclosureSEC source: 0001093557-21-000072 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,307 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,301 | $0.00 | $5.30 |
DisclosureSEC source: 0001093557-21-000050 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,873 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,256 | $397.35 | $2,088,490.00 |
DisclosureSEC source: 0001093557-20-000260 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,567 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,297 | $398.30 | $1,313,201.69 |
DisclosureSEC source: 0001093557-20-000248 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,823 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,283 | $398.30 | $511,021.47 |
DisclosureSEC source: 0001093557-20-000248 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,120 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 22,722 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 7,494 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $370.39 | $92,598.50 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 10 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,376 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $370.35 to $370.57. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,239 | $370.05 | $828,533.44 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 9 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,626 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $369.30 to $370.27. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $368.29 | $110,487.51 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 8 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,865 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $367.99 to $368.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $367.18 | $91,795.50 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 7 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,165 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $366.91 to $367.32. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $366.62 | $146,649.44 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 6 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,415 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $365.87 to $366.81. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,402 | $365.03 | $511,772.20 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 5 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,815 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $364.44 to $365.39. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.